BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Garg AD, More S, Rufo N, Mece O, Sassano ML, Agostinis P, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics. Oncoimmunology 2017;6:e1386829. [PMID: 29209573 DOI: 10.1080/2162402X.2017.1386829] [Cited by in Crossref: 124] [Cited by in F6Publishing: 77] [Article Influence: 24.8] [Reference Citation Analysis]
Number Citing Articles
1 Versteven M, Van den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Dendritic Cells and Programmed Death-1 Blockade: A Joint Venture to Combat Cancer. Front Immunol 2018;9:394. [PMID: 29599770 DOI: 10.3389/fimmu.2018.00394] [Cited by in Crossref: 53] [Cited by in F6Publishing: 52] [Article Influence: 13.3] [Reference Citation Analysis]
2 Ye J, Mills BN, Zhao T, Han BJ, Murphy JD, Patel AP, Johnston CJ, Lord EM, Belt BA, Linehan DC, Gerber SA. Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer. Cancer Immunol Res 2020;8:94-107. [PMID: 31719057 DOI: 10.1158/2326-6066.CIR-19-0373] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
3 Cueto FJ, Del Fresno C, Brandi P, Combes AJ, Hernández-García E, Sánchez-Paulete AR, Enamorado M, Bromley CP, Gomez MJ, Conde-Garrosa R, Mañes S, Zelenay S, Melero I, Iborra S, Krummel MF, Sancho D. DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells. J Immunother Cancer 2021;9:e002054. [PMID: 33980589 DOI: 10.1136/jitc-2020-002054] [Reference Citation Analysis]
4 Fan C, Li C, Lu S, Lai X, Wang S, Liu X, Song Y, Deng Y. Polysialic Acid Self-assembled Nanocomplexes for Neutrophil-Based Immunotherapy to Suppress Lung Metastasis of Breast Cancer. AAPS PharmSciTech 2022;23:109. [PMID: 35411426 DOI: 10.1208/s12249-022-02243-7] [Reference Citation Analysis]
5 Romano E, Rufo N, Korf H, Mathieu C, Garg AD, Agostinis P. BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells. Oncotarget 2018;9:17631-44. [PMID: 29707136 DOI: 10.18632/oncotarget.24815] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
6 Ortiz-aguirre JP, Velandia-vargas EA, Rodríguez-bohorquez OM, Amaya-ramírez D, Bernal-estévez D, Parra-lópez CA. Inmunoterapia personalizada contra el cáncer basada en neoantígenos. Revisión de la literatura. Rev Fac Med 2021;69:e81633. [DOI: 10.15446/revfacmed.v69n3.81633] [Reference Citation Analysis]
7 Zhang Y, Yang S, Yang Y, Liu T. Resveratrol induces immunogenic cell death of human and murine ovarian carcinoma cells. Infect Agent Cancer 2019;14:27. [PMID: 31636696 DOI: 10.1186/s13027-019-0247-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
8 Wang SJ, Haffty B. Radiotherapy as a New Player in Immuno-Oncology. Cancers (Basel). 2018;10. [PMID: 30558196 DOI: 10.3390/cancers10120515] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
9 He Y, Liu T, Dai S, Xu Z, Wang L, Luo F. Tumor-Associated Extracellular Matrix: How to Be a Potential Aide to Anti-tumor Immunotherapy? Front Cell Dev Biol 2021;9:739161. [PMID: 34733848 DOI: 10.3389/fcell.2021.739161] [Reference Citation Analysis]
10 Nath S, Obaid G, Hasan T. The Course of Immune Stimulation by Photodynamic Therapy: Bridging Fundamentals of Photochemically Induced Immunogenic Cell Death to the Enrichment of T-Cell Repertoire. Photochem Photobiol 2019;95:1288-305. [PMID: 31602649 DOI: 10.1111/php.13173] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
11 Sprooten J, Ceusters J, Coosemans A, Agostinis P, De Vleeschouwer S, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: dendritic cell vaccination for cancer immunotherapy. Oncoimmunology 2019;8:e1638212. [PMID: 31646087 DOI: 10.1080/2162402X.2019.1638212] [Cited by in Crossref: 51] [Cited by in F6Publishing: 35] [Article Influence: 17.0] [Reference Citation Analysis]
12 Felley-Bosco E. Special Issue on Mechanisms of Mesothelioma Heterogeneity: Highlights and Open Questions. Int J Mol Sci 2018;19:E3560. [PMID: 30424481 DOI: 10.3390/ijms19113560] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
13 Rosales C. Neutrophil: A Cell with Many Roles in Inflammation or Several Cell Types? Front Physiol 2018;9:113. [PMID: 29515456 DOI: 10.3389/fphys.2018.00113] [Cited by in Crossref: 294] [Cited by in F6Publishing: 279] [Article Influence: 73.5] [Reference Citation Analysis]
14 Rapoport BL, Anderson R. Realizing the Clinical Potential of Immunogenic Cell Death in Cancer Chemotherapy and Radiotherapy. Int J Mol Sci 2019;20:E959. [PMID: 30813267 DOI: 10.3390/ijms20040959] [Cited by in Crossref: 48] [Cited by in F6Publishing: 46] [Article Influence: 16.0] [Reference Citation Analysis]
15 Chen KTJ, Gilabert-Oriol R, Bally MB, Leung AWY. Recent Treatment Advances and the Role of Nanotechnology, Combination Products, and Immunotherapy in Changing the Therapeutic Landscape of Acute Myeloid Leukemia. Pharm Res 2019;36:125. [PMID: 31236772 DOI: 10.1007/s11095-019-2654-z] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
16 Wang Y, Xie W, Humeau J, Chen G, Liu P, Pol J, Zhang Z, Kepp O, Kroemer G. Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy. J Immunother Cancer 2020;8:e000462. [PMID: 32221018 DOI: 10.1136/jitc-2019-000462] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
17 Serrano-Del Valle A, Anel A, Naval J, Marzo I. Immunogenic Cell Death and Immunotherapy of Multiple Myeloma. Front Cell Dev Biol 2019;7:50. [PMID: 31041312 DOI: 10.3389/fcell.2019.00050] [Cited by in Crossref: 54] [Cited by in F6Publishing: 56] [Article Influence: 18.0] [Reference Citation Analysis]
18 Qin X, Denton WD, Huiting LN, Smith KS, Feng H. Unraveling the regulatory role of endoplasmic-reticulum-associated degradation in tumor immunity. Crit Rev Biochem Mol Biol 2020;55:322-53. [PMID: 32633575 DOI: 10.1080/10409238.2020.1784085] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Huang X, Tang T, Zhang G, Hong Z, Xu J, Yadav DK, Bai X, Liang T. Genomic investigation of co-targeting tumor immune microenvironment and immune checkpoints in pan-cancer immunotherapy. NPJ Precis Oncol 2020;4:29. [PMID: 33299118 DOI: 10.1038/s41698-020-00136-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
20 Aznar MA, Planelles L, Perez-Olivares M, Molina C, Garasa S, Etxeberría I, Perez G, Rodriguez I, Bolaños E, Lopez-Casas P, Rodriguez-Ruiz ME, Perez-Gracia JL, Marquez-Rodas I, Teijeira A, Quintero M, Melero I. Immunotherapeutic effects of intratumoral nanoplexed poly I:C. J Immunother Cancer 2019;7:116. [PMID: 31046839 DOI: 10.1186/s40425-019-0568-2] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 11.0] [Reference Citation Analysis]
21 Davola ME, Mossman KL. Oncolytic viruses: how "lytic" must they be for therapeutic efficacy? Oncoimmunology 2019;8:e1581528. [PMID: 31069150 DOI: 10.1080/2162402X.2019.1596006] [Cited by in Crossref: 44] [Cited by in F6Publishing: 28] [Article Influence: 14.7] [Reference Citation Analysis]
22 Assenat E, Pageaux GP, Thézenas S, Peron JM, Bécouarn Y, Seitz JF, Merle P, Blanc JF, Bouché O, Ramdani M, Poujol S, de Forges H, Ychou M, Boige V. Sorafenib alone vs. sorafenib plus GEMOX as 1st-line treatment for advanced HCC: the phase II randomised PRODIGE 10 trial. Br J Cancer 2019;120:896-902. [PMID: 30944458 DOI: 10.1038/s41416-019-0443-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
23 Khoury A, Sakoff JA, Gilbert J, Scott KF, Karan S, Gordon CP, Aldrich-wright JR. Cyclooxygenase-Inhibiting Platinum(IV) Prodrugs with Potent Anticancer Activity. Pharmaceutics 2022;14:787. [DOI: 10.3390/pharmaceutics14040787] [Reference Citation Analysis]
24 Ajina R, Zahavi DJ, Zhang YW, Weiner LM. Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies. Semin Cancer Biol 2020;65:28-37. [PMID: 31866479 DOI: 10.1016/j.semcancer.2019.12.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Smith M, García-Martínez E, Pitter MR, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Toll-like receptor agonists in cancer immunotherapy. Oncoimmunology 2018;7:e1526250. [PMID: 30524908 DOI: 10.1080/2162402X.2018.1526250] [Cited by in Crossref: 90] [Cited by in F6Publishing: 44] [Article Influence: 22.5] [Reference Citation Analysis]
26 Sen S, Won M, Levine MS, Noh Y, Sedgwick AC, Kim JS, Sessler JL, Arambula JF. Metal-based anticancer agents as immunogenic cell death inducers: the past, present, and future. Chem Soc Rev 2022. [PMID: 35099487 DOI: 10.1039/d1cs00417d] [Reference Citation Analysis]
27 Lenzo FL, Kato S, Pabla S, DePietro P, Nesline MK, Conroy JM, Burgher B, Glenn ST, Kuvshinoff B, Kurzrock R, Morrison C. Immune profiling and immunotherapeutic targets in pancreatic cancer. Ann Transl Med 2021;9:119. [PMID: 33569421 DOI: 10.21037/atm-20-1076] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
28 Huang Z, Hu H. Arginine Deiminase Induces Immunogenic Cell Death and Is Enhanced by N-acetylcysteine in Murine MC38 Colorectal Cancer Cells and MDA-MB-231 Human Breast Cancer Cells In Vitro. Molecules 2021;26:511. [PMID: 33478072 DOI: 10.3390/molecules26020511] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
29 Doix B, Trempolec N, Riant O, Feron O. Low Photosensitizer Dose and Early Radiotherapy Enhance Antitumor Immune Response of Photodynamic Therapy-Based Dendritic Cell Vaccination. Front Oncol 2019;9:811. [PMID: 31508370 DOI: 10.3389/fonc.2019.00811] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
30 Eriau E, Paillet J, Kroemer G, Pol JG. Metabolic Reprogramming by Reduced Calorie Intake or Pharmacological Caloric Restriction Mimetics for Improved Cancer Immunotherapy. Cancers (Basel) 2021;13:1260. [PMID: 33809187 DOI: 10.3390/cancers13061260] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Iribarren K, Buque A, Mondragon L, Xie W, Lévesque S, Pol J, Zitvogel L, Kepp O, Kroemer G. Anticancer effects of anti-CD47 immunotherapy in vivo. Oncoimmunology 2019;8:1550619. [PMID: 30723582 DOI: 10.1080/2162402X.2018.1550619] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
32 Du B, Waxman DJ. Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models. Cancer Lett 2020;470:170-80. [PMID: 31765733 DOI: 10.1016/j.canlet.2019.11.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
33 Matsushita M, Kawaguchi M. Immunomodulatory Effects of Drugs for Effective Cancer Immunotherapy. J Oncol 2018;2018:8653489. [PMID: 30498512 DOI: 10.1155/2018/8653489] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
34 García-Foncillas J, Sunakawa Y, Aderka D, Wainberg Z, Ronga P, Witzler P, Stintzing S. Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors. Front Oncol 2019;9:849. [PMID: 31616627 DOI: 10.3389/fonc.2019.00849] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 14.3] [Reference Citation Analysis]
35 Scirocchi F, Napoletano C, Pace A, Rahimi Koshkaki H, Di Filippo A, Zizzari IG, Nuti M, Rughetti A. Immunogenic Cell Death and Immunomodulatory Effects of Cabozantinib. Front Oncol 2021;11:755433. [PMID: 34745989 DOI: 10.3389/fonc.2021.755433] [Reference Citation Analysis]
36 Tukaramrao DB, Malla S, Saraiya S, Hanely RA, Ray A, Kumari S, Raman D, Tiwari AK. A Novel Thienopyrimidine Analog, TPH104, Mediates Immunogenic Cell Death in Triple-Negative Breast Cancer Cells. Cancers (Basel) 2021;13:1954. [PMID: 33919653 DOI: 10.3390/cancers13081954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
37 Qiao M, Jiang T, Zhou C. Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. J Thorac Dis 2018;10:S1534-46. [PMID: 29951304 DOI: 10.21037/jtd.2018.04.99] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
38 Humeau J, Sauvat A, Cerrato G, Xie W, Loos F, Iannantuoni F, Bezu L, Lévesque S, Paillet J, Pol J, Leduc M, Zitvogel L, de Thé H, Kepp O, Kroemer G. Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress. EMBO Mol Med 2020;12:e11622. [PMID: 32323922 DOI: 10.15252/emmm.201911622] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 9.5] [Reference Citation Analysis]
39 Zouein J, Haddad FG, Eid R, Kourie HR. The combination of immune checkpoint inhibitors and chemotherapy in advanced non-small-cell lung cancer: the rational choice. Immunotherapy 2021. [PMID: 34865502 DOI: 10.2217/imt-2021-0014] [Reference Citation Analysis]
40 Jiang W, Zhou H, Wang Q, Chen Z, Dong W, Guo Z, Li Y, Zhao W, Zhan M, Wang Y, Lu L. High drug loading and pH-responsive nanomedicines driven by dynamic boronate covalent chemistry for potent cancer immunotherapy. Nano Res 2021;14:3913-20. [DOI: 10.1007/s12274-021-3314-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
41 Sveen A, Kopetz S, Lothe RA. Biomarker-guided therapy for colorectal cancer: strength in complexity. Nat Rev Clin Oncol 2020;17:11-32. [PMID: 31289352 DOI: 10.1038/s41571-019-0241-1] [Cited by in Crossref: 67] [Cited by in F6Publishing: 68] [Article Influence: 22.3] [Reference Citation Analysis]
42 Mardi A, Shirokova AV, Mohammed RN, Keshavarz A, Zekiy AO, Thangavelu L, Mohamad TAM, Marofi F, Shomali N, Zamani A, Akbari M. Biological causes of immunogenic cancer cell death (ICD) and anti-tumor therapy; Combination of Oncolytic virus-based immunotherapy and CAR T-cell therapy for ICD induction. Cancer Cell Int 2022;22:168. [PMID: 35488303 DOI: 10.1186/s12935-022-02585-z] [Reference Citation Analysis]
43 Bezu L, Kepp O, Cerrato G, Pol J, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Peptide-based vaccines in anticancer therapy. Oncoimmunology 2018;7:e1511506. [PMID: 30524907 DOI: 10.1080/2162402X.2018.1511506] [Cited by in Crossref: 66] [Cited by in F6Publishing: 50] [Article Influence: 16.5] [Reference Citation Analysis]
44 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Reference Citation Analysis]
45 Lévesque S, Pol JG, Ferrere G, Galluzzi L, Zitvogel L, Kroemer G. Trial watch: dietary interventions for cancer therapy. Oncoimmunology 2019;8:1591878. [PMID: 31143510 DOI: 10.1080/2162402X.2019.1591878] [Cited by in Crossref: 26] [Cited by in F6Publishing: 13] [Article Influence: 8.7] [Reference Citation Analysis]
46 Tang T, Huang X, Zhang G, Hong Z, Bai X, Liang T. Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther 2021;6:72. [PMID: 33608497 DOI: 10.1038/s41392-020-00449-4] [Cited by in Crossref: 2] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
47 Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Morschhauser F, Brice P, Garciaz S, Borel C, Ysebaert L, Obéric L, Lazarovici J, Deau B, Dupuis J, Chauchet A, Abraham J, Bijou F, Stamatoullas-Bastard A, Malfuson JV, Golfier C, Laurent C, Pericart S, Traverse-Glehen A, Kanoun S, Filleron T, Casasnovas RO, Ghesquières H. Efficacy of chemotherapy or chemo-anti-PD-1 combination after failed anti-PD-1 therapy for relapsed and refractory Hodgkin lymphoma: A series from Lysa centers. Am J Hematol 2018. [PMID: 29884994 DOI: 10.1002/ajh.25154] [Cited by in Crossref: 58] [Cited by in F6Publishing: 51] [Article Influence: 14.5] [Reference Citation Analysis]
48 Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature 2019;574:45-56. [PMID: 31578484 DOI: 10.1038/s41586-019-1593-5] [Cited by in Crossref: 166] [Cited by in F6Publishing: 152] [Article Influence: 55.3] [Reference Citation Analysis]
49 Li W, Yang J, Luo L, Jiang M, Qin B, Yin H, Zhu C, Yuan X, Zhang J, Luo Z, Du Y, Li Q, Lou Y, Qiu Y, You J. Targeting photodynamic and photothermal therapy to the endoplasmic reticulum enhances immunogenic cancer cell death. Nat Commun 2019;10:3349. [PMID: 31350406 DOI: 10.1038/s41467-019-11269-8] [Cited by in Crossref: 163] [Cited by in F6Publishing: 154] [Article Influence: 54.3] [Reference Citation Analysis]
50 Reyes-Ruiz A, Calvillo-Rodriguez KM, Martínez-Torres AC, Rodríguez-Padilla C. The bovine dialysable leukocyte extract IMMUNEPOTENT CRP induces immunogenic cell death in breast cancer cells leading to long-term antitumour memory. Br J Cancer 2021;124:1398-410. [PMID: 33531687 DOI: 10.1038/s41416-020-01256-y] [Reference Citation Analysis]
51 Kepp O, Sauvat A, Leduc M, Forveille S, Liu P, Zhao L, Bezu L, Xie W, Zitvogel L, Kroemer G. A fluorescent biosensor-based platform for the discovery of immunogenic cancer cell death inducers. Oncoimmunology 2019;8:1606665. [PMID: 31413915 DOI: 10.1080/2162402X.2019.1606665] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
52 Xu J, Zheng Q, Cheng X, Hu S, Zhang C, Zhou X, Sun P, Wang W, Su Z, Zou T, Song Z, Xia Y, Yi X, Gao Y. Chemo-photodynamic therapy with light-triggered disassembly of theranostic nanoplatform in combination with checkpoint blockade for immunotherapy of hepatocellular carcinoma. J Nanobiotechnology 2021;19:355. [PMID: 34717654 DOI: 10.1186/s12951-021-01101-1] [Reference Citation Analysis]
53 Dörrie J, Schaft N, Schuler G, Schuler-Thurner B. Therapeutic Cancer Vaccination with Ex Vivo RNA-Transfected Dendritic Cells-An Update. Pharmaceutics 2020;12:E92. [PMID: 31979205 DOI: 10.3390/pharmaceutics12020092] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 8.0] [Reference Citation Analysis]
54 Papadia P, Micoli K, Barbanente A, Ditaranto N, Hoeschele JD, Natile G, Marzano C, Gandin V, Margiotta N. Platinum(IV) Complexes of trans-1,2-diamino-4-cyclohexene: Prodrugs Affording an Oxaliplatin Analogue that Overcomes Cancer Resistance. Int J Mol Sci 2020;21:E2325. [PMID: 32230896 DOI: 10.3390/ijms21072325] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
55 Louttit C, Park KS, Moon JJ. Bioinspired nucleic acid structures for immune modulation. Biomaterials 2019;217:119287. [PMID: 31247511 DOI: 10.1016/j.biomaterials.2019.119287] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.7] [Reference Citation Analysis]
56 Quiros-Fernandez I, Figueroa-Protti L, Arias-Arias JL, Brenes-Cordero N, Siles F, Mora J, Mora-Rodríguez RA. Perturbation-Based Modeling Unveils the Autophagic Modulation of Chemosensitivity and Immunogenicity in Breast Cancer Cells. Metabolites 2021;11:637. [PMID: 34564453 DOI: 10.3390/metabo11090637] [Reference Citation Analysis]
57 Lévesque S, Le Naour J, Pietrocola F, Paillet J, Kremer M, Castoldi F, Baracco EE, Wang Y, Vacchelli E, Stoll G, Jolly A, De La Grange P, Zitvogel L, Kroemer G, Pol JG. A synergistic triad of chemotherapy, immune checkpoint inhibitors, and caloric restriction mimetics eradicates tumors in mice. Oncoimmunology 2019;8:e1657375. [PMID: 31646107 DOI: 10.1080/2162402X.2019.1657375] [Cited by in Crossref: 29] [Cited by in F6Publishing: 23] [Article Influence: 9.7] [Reference Citation Analysis]
58 Uscanga-Palomeque AC, Calvillo-Rodríguez KM, Gómez-Morales L, Lardé E, Denèfle T, Caballero-Hernández D, Merle-Béral H, Susin SA, Karoyan P, Martínez-Torres AC, Rodríguez-Padilla C. CD47 agonist peptide PKHB1 induces immunogenic cell death in T-cell acute lymphoblastic leukemia cells. Cancer Sci 2019;110:256-68. [PMID: 30460757 DOI: 10.1111/cas.13885] [Cited by in Crossref: 18] [Cited by in F6Publishing: 21] [Article Influence: 4.5] [Reference Citation Analysis]
59 Jian M, Ren L, He G, Lin Q, Tang W, Chen Y, Chen J, Liu T, Ji M, Wei Y, Chang W, Xu J. A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases. J Transl Med 2020;18:234. [PMID: 32532289 DOI: 10.1186/s12967-020-02407-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
60 Casadei B, Argnani L, Morigi A, Lolli G, Broccoli A, Pellegrini C, Nanni L, Stefoni V, Coppola PE, Carella M, Cavo M, Zinzani PL. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med 2020;9:7830-6. [PMID: 32881376 DOI: 10.1002/cam4.3262] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
61 Sansone C, Bruno A, Piscitelli C, Baci D, Fontana A, Brunet C, Noonan DM, Albini A. Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy. Cells 2021;10:231. [PMID: 33504012 DOI: 10.3390/cells10020231] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Yamazaki T, Buqué A, Ames TD, Galluzzi L. PT-112 induces immunogenic cell death and synergizes with immune checkpoint blockers in mouse tumor models. Oncoimmunology 2020;9:1721810. [PMID: 32117585 DOI: 10.1080/2162402X.2020.1721810] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 8.0] [Reference Citation Analysis]
63 Elhassanny AEM, Soliman E, Marie M, McGuire P, Gul W, ElSohly M, Van Dross R. Heme-Dependent ER Stress Apoptosis: A Mechanism for the Selective Toxicity of the Dihydroartemisinin, NSC735847, in Colorectal Cancer Cells. Front Oncol 2020;10:965. [PMID: 32626657 DOI: 10.3389/fonc.2020.00965] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
64 Fabian KP, Wolfson B, Hodge JW. From Immunogenic Cell Death to Immunogenic Modulation: Select Chemotherapy Regimens Induce a Spectrum of Immune-Enhancing Activities in the Tumor Microenvironment. Front Oncol 2021;11:728018. [PMID: 34497771 DOI: 10.3389/fonc.2021.728018] [Reference Citation Analysis]
65 Gao J, Deng F, Jia W. Inhibition of Indoleamine 2,3-Dioxygenase Enhances the Therapeutic Efficacy of Immunogenic Chemotherapeutics in Breast Cancer. J Breast Cancer 2019;22:196-209. [PMID: 31281723 DOI: 10.4048/jbc.2019.22.e23] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 3.3] [Reference Citation Analysis]
66 Patel SA, Minn AJ. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies. Immunity 2018;48:417-33. [PMID: 29562193 DOI: 10.1016/j.immuni.2018.03.007] [Cited by in Crossref: 196] [Cited by in F6Publishing: 191] [Article Influence: 49.0] [Reference Citation Analysis]
67 Zhou L, Zhang P, Wang H, Wang D, Li Y. Smart Nanosized Drug Delivery Systems Inducing Immunogenic Cell Death for Combination with Cancer Immunotherapy. Acc Chem Res 2020;53:1761-72. [PMID: 32819102 DOI: 10.1021/acs.accounts.0c00254] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 9.0] [Reference Citation Analysis]
68 Humeau J, Le Naour J, Galluzzi L, Kroemer G, Pol JG. Trial watch: intratumoral immunotherapy. Oncoimmunology 2021;10:1984677. [PMID: 34676147 DOI: 10.1080/2162402X.2021.1984677] [Reference Citation Analysis]
69 Lu Y, Shi Y, You J. Strategy and clinical application of up-regulating cross presentation by DCs in anti-tumor therapy. J Control Release 2021;341:184-205. [PMID: 34774890 DOI: 10.1016/j.jconrel.2021.11.011] [Reference Citation Analysis]
70 García-Martínez E, Smith M, Buqué A, Aranda F, de la Peña FA, Ivars A, Cánovas MS, Conesa MAV, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunostimulation with recombinant cytokines for cancer therapy. Oncoimmunology 2018;7:e1433982. [PMID: 29872569 DOI: 10.1080/2162402X.2018.1433982] [Cited by in Crossref: 25] [Cited by in F6Publishing: 9] [Article Influence: 6.3] [Reference Citation Analysis]
71 Tulotta C, Lefley DV, Moore CK, Amariutei AE, Spicer-Hadlington AR, Quayle LA, Hughes RO, Ahmed K, Cookson V, Evans CA, Vadakekolathu J, Heath P, Francis S, Pinteaux E, Pockley AG, Ottewell PD. IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. NPJ Breast Cancer 2021;7:95. [PMID: 34290237 DOI: 10.1038/s41523-021-00305-w] [Reference Citation Analysis]
72 Shao L, Ye Q, Jia M. miR-130-3p Promotes MTX-Induced Immune Killing of Hepatocellular Carcinoma Cells by Targeting EPHB4. J Healthc Eng 2021;2021:4650794. [PMID: 34336153 DOI: 10.1155/2021/4650794] [Reference Citation Analysis]
73 Anderson R, Theron AJ, Rapoport BL. Immunopathogenesis of Immune Checkpoint Inhibitor-Related Adverse Events: Roles of the Intestinal Microbiome and Th17 Cells. Front Immunol 2019;10:2254. [PMID: 31616428 DOI: 10.3389/fimmu.2019.02254] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
74 Hayashi K, Nikolos F, Lee YC, Jain A, Tsouko E, Gao H, Kasabyan A, Leung HE, Osipov A, Jung SY, Kurtova AV, Chan KS. Tipping the immunostimulatory and inhibitory DAMP balance to harness immunogenic cell death. Nat Commun 2020;11:6299. [PMID: 33288764 DOI: 10.1038/s41467-020-19970-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
75 Tatsuno K, Yamazaki T, Hanlon D, Han P, Robinson E, Sobolev O, Yurter A, Rivera-Molina F, Arshad N, Edelson RL, Galluzzi L. Extracorporeal photochemotherapy induces bona fide immunogenic cell death. Cell Death Dis 2019;10:578. [PMID: 31371700 DOI: 10.1038/s41419-019-1819-3] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 8.0] [Reference Citation Analysis]
76 Hernández ÁP, Juanes-Velasco P, Landeira-Viñuela A, Bareke H, Montalvillo E, Góngora R, Fuentes M. Restoring the Immunity in the Tumor Microenvironment: Insights into Immunogenic Cell Death in Onco-Therapies. Cancers (Basel) 2021;13:2821. [PMID: 34198850 DOI: 10.3390/cancers13112821] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
77 Pol JG, Lévesque S, Workenhe ST, Gujar S, Le Boeuf F, Clements DR, Fahrner JE, Fend L, Bell JC, Mossman KL, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors. Oncoimmunology 2018;7:e1503032. [PMID: 30524901 DOI: 10.1080/2162402X.2018.1503032] [Cited by in Crossref: 45] [Cited by in F6Publishing: 34] [Article Influence: 11.3] [Reference Citation Analysis]
78 El Sissy C, Kirilovsky A, Zeitoun G, Marliot F, Haicheur N, Lagorce-Pagès C, Galon J, Pagès F. Therapeutic Implications of the Immunoscore in Patients with Colorectal Cancer. Cancers (Basel) 2021;13:1281. [PMID: 33805758 DOI: 10.3390/cancers13061281] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
79 Sun Y, Feng X, Wan C, Lovell JF, Jin H, Ding J. Role of nanoparticle-mediated immunogenic cell death in cancer immunotherapy. Asian J Pharm Sci 2021;16:129-32. [PMID: 33995609 DOI: 10.1016/j.ajps.2020.05.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
80 Li T, Liu T, Zhu W, Xie S, Zhao Z, Feng B, Guo H, Yang R. Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects. Clin Med Insights Oncol 2021;15:11795549211035540. [PMID: 34408525 DOI: 10.1177/11795549211035540] [Reference Citation Analysis]
81 Castoldi F, Vacchelli E, Zitvogel L, Maiuri MC, Pietrocola F, Kroemer G. Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy. Oncoimmunology 2019;8:e1498285. [PMID: 30546941 DOI: 10.1080/2162402X.2018.1498285] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
82 Arai H, Xiao Y, Loupakis F, Kawanishi N, Wang J, Battaglin F, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Falcone A, Millstein J, Lenz HJ. Immunogenic cell death pathway polymorphisms for predicting oxaliplatin efficacy in metastatic colorectal cancer. J Immunother Cancer 2020;8:e001714. [PMID: 33172883 DOI: 10.1136/jitc-2020-001714] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
83 Vanmeerbeek I, Sprooten J, De Ruysscher D, Tejpar S, Vandenberghe P, Fucikova J, Spisek R, Zitvogel L, Kroemer G, Galluzzi L, Garg AD. Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. Oncoimmunology 2020;9:1703449. [PMID: 32002302 DOI: 10.1080/2162402X.2019.1703449] [Cited by in Crossref: 58] [Cited by in F6Publishing: 41] [Article Influence: 29.0] [Reference Citation Analysis]
84 Horrevorts SK, Stolk DA, van de Ven R, Hulst M, van Het Hof B, Duinkerken S, Heineke MH, Ma W, Dusoswa SA, Nieuwland R, Garcia-Vallejo JJ, van de Loosdrecht AA, de Gruijl TD, van Vliet SJ, van Kooyk Y. Glycan-Modified Apoptotic Melanoma-Derived Extracellular Vesicles as Antigen Source for Anti-Tumor Vaccination. Cancers (Basel) 2019;11:E1266. [PMID: 31466401 DOI: 10.3390/cancers11091266] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
85 Skoniecka A, Cichorek M, Tyminska A, Pelikant-Malecka I, Dziewiatkowski J. Melanization as unfavorable factor in amelanotic melanoma cell biology. Protoplasma 2021. [PMID: 33506271 DOI: 10.1007/s00709-021-01613-5] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Li X, Liu Z, Zhang A, Han C, Shen A, Jiang L, Boothman DA, Qiao J, Wang Y, Huang X, Fu YX. NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance. Nat Commun 2019;10:3251. [PMID: 31324798 DOI: 10.1038/s41467-019-11238-1] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
87 Mantovani A, Marchesi F, Jaillon S, Garlanda C, Allavena P. Tumor-associated myeloid cells: diversity and therapeutic targeting. Cell Mol Immunol 2021;18:566-78. [PMID: 33473192 DOI: 10.1038/s41423-020-00613-4] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 9.0] [Reference Citation Analysis]
88 DeRogatis JM, Viramontes KM, Neubert EN, Tinoco R. PSGL-1 Immune Checkpoint Inhibition for CD4+ T Cell Cancer Immunotherapy. Front Immunol 2021;12:636238. [PMID: 33708224 DOI: 10.3389/fimmu.2021.636238] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
89 Alkarakooly Z, Al-Anbaky QA, Kannan K, Ali N. Metabolic reprogramming by Dichloroacetic acid potentiates photodynamic therapy of human breast adenocarcinoma MCF-7 cells. PLoS One 2018;13:e0206182. [PMID: 30352078 DOI: 10.1371/journal.pone.0206182] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
90 Aznar MA, Molina C, Teijeira A, Rodriguez I, Azpilikueta A, Garasa S, Sanchez-Paulete AR, Cordeiro L, Etxeberria I, Alvarez M, Rius-Rocabert S, Nistal-Villan E, Berraondo P, Melero I. Repurposing the yellow fever vaccine for intratumoral immunotherapy. EMBO Mol Med 2020;12:e10375. [PMID: 31746149 DOI: 10.15252/emmm.201910375] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
91 Hof J, Kok K, Sijmons RH, de Jong KP. Systematic Review of the Prognostic Role of the Immune System After Surgery of Colorectal Liver Metastases. Front Oncol 2019;9:148. [PMID: 30941301 DOI: 10.3389/fonc.2019.00148] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
92 Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, Hirata H, Yano Y, Yokota S, Kinehara Y, Naito Y, Otsuka T, Kanazu M, Kuroyama M, Hamaguchi M, Koba T, Futami Y, Ishijima M, Suga Y, Akazawa Y, Machiyama H, Iwahori K, Takamatsu H, Nagatomo I, Takeda Y, Kida H, Akbay EA, Hammerman PS, Wong KK, Dranoff G, Mori M, Kijima T, Kumanogoh A. Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight 2018;3:59125. [PMID: 30282824 DOI: 10.1172/jci.insight.59125] [Cited by in Crossref: 58] [Cited by in F6Publishing: 61] [Article Influence: 14.5] [Reference Citation Analysis]